Spain is a leader in research into targeted therapy for colorectal cancer

Compilation
During Congress of the Spanish Society of Medical Oncology (SEOM)held from October 15 to 18, the results were summed up Fresco-2 Phase III Clinical Study. This allowed us to evaluate Efficacy and safety of fructintinib in adult patients with refractory metastatic colorectal cancer (mCRC). This treatment includes first targeted therapy approved in more than a decade for this pathology. In this way, it gives new hope to patients who no longer respond to traditional treatments.

Spain played a fundamental role in this scientific breakthrough.being the country that provided the most patients to participate in the study. Total 180 patients received treatment in 16 national centers. This confirms the country’s leading position in oncology research. The results of this study have already led to the European Commission’s approval of fructintinib in June as monotherapy for patients with refractory mCRC who have exhausted standard treatments.

A total of 180 patients were treated with this targeted therapy at 16 national centers.

Fresco-2 test compared the use of fructintinib plus best supportive care (BSC) and placebo plus BSC. The results were encouraging, demonstrating significant improvements in overall survival and progression-free survival in patients treated with fructintinib. regardless of previous therapy received. This therapy marks Milestone in the treatment of colorectal cancer refractory, which presents a difficult prognosis and limited therapeutic options.

Doctor Rocio Garcia CarboneroCoordinator of the Department of Digestive and Neuroendocrine Tumors of the University Hospital October 12emphasized the importance of this new treatment: “Patients with metastatic colorectal cancer face significant challenges, both due to the disease itself and the side effects of treatment. Each new line of treatment helps transform the disease into a chronic form.something important for these advanced patients“

The results of fructintinib represent an important milestone in the fight against colorectal cancer, a disease with a difficult prognosis.

He security profile fructintinib was also noted. He 20% of patients taking the drug were forced to stop treatment. due to adverse consequences. On the other hand, in the placebo group, the intake had to be interrupted after some time. 21% of cases. The full results of the study were published in Lancet in June 2023, which confirms the reliability of the data.

Fernando Valpuestahead of oncology department in the country Takedaexpressed satisfaction with Spain’s contribution to the study: “For the first time in more than a decade, patients with refractory metastatic colorectal cancer have a new treatment option. Spain’s participation has played a key role in this development and we are committed to offering a therapy with a manageable and effective safety profile.regardless of previous therapy received“

This is a pre-posting Spain is at the forefront of cancer research. In addition, it offers new therapeutic options for patients with refractory colorectal cancer, significantly improving their length and quality of life.